Sign In
Buy ABT
$93.24
+2.73 (+3.02%)
At Close: Jun 25, 2026
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
10:31am, Thursday, 05'th Jun 2025
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note
06:56pm, Wednesday, 04'th Jun 2025
Abbott (ABT) closed at $132.96 in the latest trading session, marking a -0.56% move from the prior day.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
10:06am, Wednesday, 04'th Jun 2025
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott Benefits From Libre & Biosimilars Amid FX, Cost Headwinds
11:10am, Friday, 30'th May 2025
ABT sees a 21.6% jump in CGM sales and growing global diagnostics demand, while FX and macro pressure temper its outlook.
Abbott (ABT) Rises Higher Than Market: Key Facts
06:51pm, Thursday, 29'th May 2025
Abbott (ABT) closed the most recent trading day at $132.85, moving +0.63% from the previous trading session.
Abbott Stock Gains Following FDA Approval of the Tendyne System
10:25am, Wednesday, 28'th May 2025
ABT wins FDA approval for its Tendyne TMVR system, offering a minimally invasive mitral valve replacement for high-risk patients with severe MAC.
Best Dividend Aristocrats For June 2025
10:15pm, Tuesday, 27'th May 2025
Dividend Aristocrats have slightly outperformed the S&P 500 year-to-date, despite underperforming in April and May. Dividend growth remains robust, with 41 of 69 Aristocrats announcing increases in 20
Abbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery
09:00am, Tuesday, 27'th May 2025
The Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (MAC) Tendyne offers a
Abbott Laboratories: Why Wall Street's Skepticism Misses The Real Story
05:09am, Tuesday, 27'th May 2025
Abbott remains a Buy at $131 for its steady cash flow, strong fundamentals, and long-term healthcare growth, despite short-term revenue concerns. Wall Street underestimates ABT's operational disciplin
4 Dividend Aristocrats Are Absolutely Crushing the S&P 500 in 2025
07:41am, Friday, 23'rd May 2025
Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.
2 Dividend Stocks to Buy With $500 and Hold Forever
06:30am, Friday, 23'rd May 2025
Broader equities have been volatile this year, but that's par for the course. The fact that the stock market will sometimes go through erratic periods is not a good reason not to invest.
Abbott vs. Medtronic: Which Dividend-Paying MedTech Stock is Better?
04:01pm, Thursday, 22'nd May 2025
With both MDT & ABT focusing on their core strengths, the stage is set for a compelling comparison. Let's see which stock is poised for greater upside.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
10:01am, Wednesday, 21'st May 2025
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Stifel Has Big Second-Half Stock Market Concerns: 5 Defensive Value Dividend Stocks Buys
01:14pm, Tuesday, 20'th May 2025
If there is one voice on Wall Street that we always listen to, it is Stifel's Barry Bannister, and with good reason.
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
10:35am, Tuesday, 20'th May 2025
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
